A Quebec medical research consent form (formulaire de consentement à la recherche médicale) is a formal written document through which a person voluntarily agrees to participate in a scientific or clinical research study after receiving complete and accurate information about the study's objectives, procedures, risks, benefits, and their rights as a participant. This document is grounded in a multi-layered legal framework that gives Quebec one of the most comprehensive legal protections for human research participants in North America.

The primary legal foundation is found in articles 20 to 25 of the Civil Code of Quebec (C.c.Q.), which address the integrity of the person and the conditions under which a person may submit to medical experimentation. Article 20 C.c.Q. permits a person to submit to any experimentation — whether it presents a risk or not — only if they provide free and informed consent. Article 21 C.c.Q. establishes additional safeguards for research involving minors (under 18) or legally incapacitated adults, requiring both a positive ethics opinion and the consent of the legal representative, with the minor's own assent also required if aged 14 or older. Article 24 C.c.Q. requires that consent to research be given in writing, and expressly provides that this consent may be withdrawn at any time without penalty — a right that cannot be waived by any contractual term.

Beyond the Civil Code, Quebec's framework for research ethics is shaped by the Loi sur les services de santé et les services sociaux (LSSSS, RLRQ, c. S-4.2), which governs health institutions and imposes specific obligations on hospitals, CLSC, and university health centers with respect to the ethical conduct of research. The federal Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS2/EPTC2), published jointly by the three major federal research funding agencies (CIHR, NSERC, and SSHRC), sets out the national standard for research ethics and is applied by all Research Ethics Boards (Comités d'éthique de la recherche, CER) in Quebec's universities and hospitals. Under the EPTC2, no research involving human participants may begin without prior review and approval by a recognized CER.

The consent form serves multiple essential functions. It is the primary tool for ensuring that the participant's consent is truly free — meaning given without pressure, inducement, or manipulation — and truly informed — meaning based on a complete understanding of what participation involves. It creates a written record of the consent that protects both the participant (by documenting their rights) and the researcher (by demonstrating that proper consent procedures were followed). It is also a key component of the ethics review process: CERs in Quebec carefully review consent forms to ensure they meet legal requirements, use plain and accessible language, and do not contain misleading or coercive language.

The good faith obligation of art. 1375 C.c.Q. applies throughout the research relationship — from the initial consent process to the final report. Researchers who obtain consent through misleading information, who fail to update participants about significant new developments during the study, or who use participant data in ways not authorized by the consent form may be held liable for breach of their legal obligations. Participants who believe their rights have been violated may file a complaint with the CER, the Commissaire à la santé et au bien-être, or the Commission d'accès à l'information du Québec (for privacy breaches), in addition to seeking civil remedies under general Quebec civil law.

A medical research consent form is required in Quebec whenever a person is invited to participate in any research study that involves interaction with human participants, collection of their personal or health data, or any intervention on their person. The requirement for a written consent form under art. 24 C.c.Q. applies broadly across all types of human research, including: clinical trials of new medications, medical devices, or therapeutic procedures conducted in hospitals, university health centers (CHU), or clinics; phase I, II, III, and IV drug trials; observational studies that involve taking biological samples (blood, tissue, DNA, urine, saliva); epidemiological studies that collect personal health information from participants; behavioral research that involves invasive psychological interventions or collection of sensitive personal information; research on vulnerable populations including minors, pregnant women, incarcerated persons, or individuals with diminished decision-making capacity; and health services research that involves accessing patient records or conducting interviews about personal health experiences.

The obligation to obtain written informed consent is particularly rigorous in the context of interventional research — studies in which participants receive experimental treatments, undergo medical procedures, or take experimental medications. In these cases, the consent form must describe in plain language the exact nature of the intervention, all known and foreseeable risks and side effects, the availability of alternative treatments, and the participant's right to refuse or withdraw at any time without affecting their regular care.

Observational research — studies that collect data through interviews, questionnaires, or review of existing records without any physical intervention — may in some cases involve a simplified consent process if the research poses minimal risk, the data is anonymized, and the CER approves a waiver of full written consent. However, even in these cases, some form of written documentation of participant agreement is typically expected under Quebec law and the EPTC2.

The consent form is also needed when a participant is being asked to consent to the future use of their biological samples or data for research purposes they did not specifically anticipate at the time of initial collection. Quebec's research ethics framework, following the EPTC2, requires that any use of biological specimens or personal data beyond the original research purpose must be subject to a new consent process or a specific waiver from the CER.

For academic and hospital research institutions in Quebec, the consent form is typically prepared by the research team and submitted to the CER as part of the ethics review package. The CER reviews the form and may require revisions to ensure it meets all legal and ethical requirements before approving the research. The final, CER-approved version of the consent form must be the one presented to participants — researchers may not use an earlier draft or a modified version without going back to the CER for re-approval.

For research projects funded by federal granting agencies such as the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), or the Social Sciences and Humanities Research Council (SSHRC), compliance with the EPTC2 is a condition of funding. Institutions that receive federal research funding have a legal and contractual obligation to ensure that all research involving human participants conducted at the institution complies with the EPTC2 requirements for informed consent. Research that proceeds without proper written consent may be subject to early termination, funding withdrawal, and regulatory penalties. For clinical trials subject to Health Canada's oversight, the Food and Drug Regulations (C.R.C., c. 870) impose additional requirements for consent documentation that go beyond the general provisions of the Civil Code of Quebec. Sponsors and researchers conducting clinical trials must maintain consent form versions that are compliant with both provincial civil law requirements and Health Canada's regulatory standards, and any changes to the consent form during the trial must be approved by the CER before being presented to participants.

A complete and legally effective Quebec medical research consent form must contain a series of carefully structured elements, each serving a distinct legal and ethical purpose. First, clear identification of the principal investigator and their institutional affiliation is required. Participants must know who is responsible for conducting the research, their qualifications, and how to reach them with questions or concerns. The name of the research institution, the relevant department or research unit, and the contact telephone and email of the researcher must all be provided.

Second, the participant's personal information must be collected and documented, including their full name, date of birth, and address. This ensures the consent is tied to a specific individual. If the research involves a minor or an incapacitated adult, the legal representative's information must also be documented, along with their authority to consent (parental authority under arts. 597-612 C.c.Q., tutorship, or mandate in case of incapacity).

Third, the research project must be described clearly and accurately. The full title of the research project, the protocol number, the objectives expressed in plain language accessible to a layperson, and the expected duration of the participant's involvement must all be disclosed. The EPTC2 requires that the consent form be written at a reading level accessible to the general public (generally recommended at a Grade 8 reading level or lower), avoiding technical jargon wherever possible.

Fourth, all research procedures must be described in detail. The consent form must describe every step the participant will undergo — from the initial screening visit to final data collection — including the frequency and duration of visits, any medications or substances the participant will take, any biological samples that will be collected, any questionnaires or assessments that will be administered, and any follow-up requirements after the main study period ends. Participants must understand exactly what they are agreeing to before signing.

Fifth, risks and inconveniences must be disclosed completely and honestly. Article 20 C.c.Q. requires the researcher to inform participants of all foreseeable risks, even if those risks are rare or unlikely. The consent form must distinguish between risks that are common but minor (such as bruising from a blood draw) and risks that are rare but serious (such as an allergic reaction to a study drug). The EPTC2 requires that risks be presented proportionally — neither downplayed to encourage participation nor exaggerated in a way that discourages participation unnecessarily.

Sixth, potential benefits must be described honestly. The consent form must distinguish between direct benefits to the participant (if the experimental treatment proves effective) and indirect benefits to society through the advancement of medical knowledge. If there are no direct benefits to the participant, this must be stated clearly. Researchers must not overstate the likely benefits of participation as a means of inducing consent.

Seventh, data confidentiality provisions are legally required under Quebec's Loi 25 and the LSSSS. The form must describe in specific terms how participant data will be coded, stored, shared, and eventually destroyed. Participants must be informed of who will have access to their data, whether data will be shared with sponsors, collaborators, or regulatory authorities, and under what circumstances.

Eighth, the right to withdraw under art. 24 C.c.Q. must be prominently stated, with specific instructions on how to exercise that right. Ninth, information about financial compensation must be transparent and accurate. Finally, the Research Ethics Board that approved the study must be identified, with contact information provided so that participants can reach the CER independently if they have concerns about the ethical conduct of the research. The document must be signed by the participant (or their legal representative) and the principal investigator, both in good faith as required by art. 1375 C.c.Q.